재생 의료 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of regenerative medicine Market

The global regenerative medicine market is poised for exponential growth, driven by innovations in cell therapy, gene therapy, tissue engineering, and platelet-rich plasma (PRP) therapies. Regenerative medicine focuses on repairing, replacing, or regenerating damaged tissues or organs using cells, tissues, or genetic material. It provides potential treatments for chronic and terminal conditions such as cancers, Parkinson's disease, Alzheimer's disease, diabetes, cardiovascular disorders, and renal diseases.

According to Fortune Business Insights, the market was valued at USD 51.65 billion in 2025, expected to grow to USD 63 billion in 2026, and projected to reach USD 555.58 billion by 2034, reflecting a remarkable CAGR of 31.27% from 2026 to 2034. North America dominated the market in 2025 with a 45.38% share, fueled by technological advancements, rapid adoption of cell and gene therapies, and a supportive regulatory environment. The U.S. market is projected to grow substantially, reaching USD 184.21 billion by 2032, driven by government-backed R&D initiatives and innovative product approvals.

Market Drivers

Increasing R&D Investments and Innovative Product Launches: Governments, private players, and academic institutions are heavily investing in regenerative medicine to develop novel therapies. For instance, in July 2022, Washington University received a grant of USD 557,000 from the NHLBI to study ETRIM72 protein for regenerating vasculature and skeletal muscles in diabetic critical limb ischemia. Similarly, Wipro and Pandorum Technologies partnered in March 2022 to integrate artificial intelligence in regenerative medicine R&D, accelerating time-to-market and improving patient outcomes.

Emerging Pipeline and Clinical Candidates: Pharmaceutical and life sciences companies are broadening applications from wound care and tissue repair to cardiology, oncology, neurology, and rare diseases. In November 2023, Sysmex Corporation entered a licensing agreement with JUNTEN BIO for immune tolerance therapies, and in June 2022, CRISPR Therapeutics reported positive Phase 1 results for its allogeneic CAR-T cell therapy CTX130 targeting solid tumors. Such developments expand product adoption and accelerate market growth.

Rising Prevalence of Chronic Diseases: Increasing incidence of diabetes, cancer, cardiovascular diseases, and orthopedic conditions is creating strong demand for advanced regenerative therapies. The orthopedics segment alone is projected to hold 40.61% of the market share in 2026, as products accelerate healing and reduce pain from musculoskeletal disorders.

Market Restraints

High Treatment Costs and Limited Reimbursement: The high cost of therapies, such as stem cell treatments ranging from USD 5,000-50,000 and gene therapy like Zolgensma at USD 2.12 million, limits accessibility. Inadequate insurance coverage often forces patients to pay out-of-pocket or rely on crowdfunding, hindering adoption. Additionally, limited approved therapies for rare genetic disorders pose barriers to growth.

Market Segmentation

By Product:

• Cell Therapy: Dominates the market with 54.87% share in 2026, widely used for autoimmune disorders, cancers, infectious diseases, and musculoskeletal injuries.
• Gene Therapy: Highest CAGR, treating rare diseases such as Spinal Muscular Atrophy, offering targeted, effective interventions.
• Tissue Engineering: Second-largest share, catering to wound care with scaffolds, biomatrices, and skin-like products.
• Platelet-Rich Plasma (PRP): Smallest share but growing in orthopedics and cosmetic applications.

By Application:

• Orthopedics: Largest segment in 2026 due to increasing bone and joint injuries.
• Oncology: High CAGR as CAR-T therapies meet unmet needs for cancer treatment.
• Wound Care: Benefiting from advanced bioengineered products for chronic wounds.
• Rare Diseases: Fastest-growing segment due to limited treatment options and increasing patient population.

By End User:

• Hospitals: Dominant with 62.54% share in 2026, driven by surgical procedures and government support.
• Clinics: Second-largest, offering specialized regenerative medicine services.
• Others: Include academic and research institutes, contributing moderately due to eligibility constraints.

Regional Insights

North America: Valued at USD 23.44 billion in 2025, projected to reach USD 27.06 billion by 2026, driven by RMAT approvals, technological adoption, and strong R&D infrastructure.

Europe: Second-largest market, supported by government funding and regulatory approvals. UK projected at USD 3.58 billion, Germany at USD 4.2 billion by 2026.

Asia Pacific: Fastest-growing, with Japan at USD 3.55 billion, China at USD 3.21 billion, and India at USD 2.01 billion by 2026, fueled by chronic disease prevalence, government initiatives, and rising disposable incomes.

Latin America & MEA: Slower growth due to low healthcare expenditure and limited awareness of therapies.

Competitive Landscape

Key players include Novartis AG, Zimmer Biomet, Gilead Sciences, Stryker, Integra LifeSciences, Kite (Gilead), CRISPR Therapeutics, bluebird bio, and Allergan (AbbVie). Companies are focusing on strategic acquisitions, R&D collaborations, and licensing agreements to strengthen product pipelines and expand global presence.

Recent Developments:

• February 2024: Iovance Biotherapeutics received FDA approval for TIL therapy (AMTAGVI) for melanoma.
• September 2023: Launch of Lynch Regenerative Medicine for advanced wound care.
• February 2023: CSL Behring and UniQure's Hemgenix approved in Europe for hemophilia B treatment.

Conclusion

The global regenerative medicine market is set to expand from USD 51.65 billion in 2025 to USD 63 billion in 2026, reaching an impressive USD 555.58 billion by 2034 at a CAGR of 31.27%. Growth is driven by R&D investments, innovative therapies, rising chronic disease prevalence, and government support. While high costs and limited reimbursement may restrain adoption, technological advancements, regulatory approvals, and strategic collaborations position the market for transformative impact in healthcare globally.

Segmentation By Product

• Cell Therapy
• Gene Therapy
• Tissue Engineering
• Platelet Rich Plasma

By Application

• Orthopedics
• Wound Care
• Oncology
• Rare Diseases
• Others

By End User

• Hospitals
• Clinics
• Others

By Region

• North America (By Product, By Application, By End User, By Country)
  • U.S.
  • Canada
• Europe (By Product, By Application, By End User, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, By Application, By End User, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, By Application, By End User, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, By Application, By End User, By Country/Sub-Region)
  • GCC
  • South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Global Financing of Companies Active in Regenerative Medicine
• 4.2. Prevalence of Chronic Diseases, By Key Countries/Regions, 2025
• 4.3. Pipeline Analysis, By Key Players
• 4.4. New Product Launches, Key Players
• 4.5. Key Industry Developments: Mergers, Acquisitions & Partnerships
• 4.6. Technological Developments in Regenerative Medicine
• 4.7. Impact of COVID-19 on the Global Market

5. Global Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Cell Therapy
  • 5.1.2. Gene Therapy
  • 5.1.3. Tissue Engineering
  • 5.1.4. Platelet Rich Plasma
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Orthopedics
  • 5.2.2. Wound Care
  • 5.2.3. Oncology
  • 5.2.4. Rare Diseases
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Cell Therapy
  • 6.1.2. Gene Therapy
  • 6.1.3. Tissue Engineering
  • 6.1.4. Platelet Rich Plasma
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Orthopedics
  • 6.2.2. Wound Care
  • 6.2.3. Oncology
  • 6.2.4. Rare Diseases
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Cell Therapy
  • 7.1.2. Gene Therapy
  • 7.1.3. Tissue Engineering
  • 7.1.4. Platelet Rich Plasma
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Orthopedics
  • 7.2.2. Wound Care
  • 7.2.3. Oncology
  • 7.2.4. Rare Diseases
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Cell Therapy
  • 8.1.2. Gene Therapy
  • 8.1.3. Tissue Engineering
  • 8.1.4. Platelet Rich Plasma
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Orthopedics
  • 8.2.2. Wound Care
  • 8.2.3. Oncology
  • 8.2.4. Rare Diseases
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Cell Therapy
  • 9.1.2. Gene Therapy
  • 9.1.3. Tissue Engineering
  • 9.1.4. Platelet Rich Plasma
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Orthopedics
  • 9.2.2. Wound Care
  • 9.2.3. Oncology
  • 9.2.4. Rare Diseases
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Regenerative Medicine Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Cell Therapy
  • 10.1.2. Gene Therapy
  • 10.1.3. Tissue Engineering
  • 10.1.4. Platelet Rich Plasma
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Orthopedics
  • 10.2.2. Wound Care
  • 10.2.3. Oncology
  • 10.2.4. Rare Diseases
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Integra LifeSciences Corporation
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Bristol-Myers Squibb Company
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Tissue Regenix
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Smith & Nephew
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. MiMedx
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Novartis AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Allergan Aesthetics (AbbVie Inc.)
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Stryker
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. American CryoStem Corporation
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Kite (Gilead Sciences, Inc.)
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. AlloSource
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. bluebird bio, Inc.
    • 11.2.12.1. Overview
    • 11.2.12.2. Products & Services
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)
  • 11.2.13. CRISPR Therapeutics
    • 11.2.13.1. Overview
    • 11.2.13.2. Products & Services
    • 11.2.13.3. SWOT Analysis
    • 11.2.13.4. Recent Developments
    • 11.2.13.5. Strategies
    • 11.2.13.6. Financials (Based on Availability)
  • 11.2.14. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
    • 11.2.14.1. Overview
    • 11.2.14.2. Products & Services
    • 11.2.14.3. SWOT Analysis
    • 11.2.14.4. Recent Developments
    • 11.2.14.5. Strategies
    • 11.2.14.6. Financials (Based on Availability)
  • 11.2.15. Tegoscience
    • 11.2.15.1. Overview
    • 11.2.15.2. Products & Services
    • 11.2.15.3. SWOT Analysis
    • 11.2.15.4. Recent Developments
    • 11.2.15.5. Strategies
    • 11.2.15.6. Financials (Based on Availability)